Search

everythinglearnresearchcommunity

for

Search:↓

Upadacitinib improved multiple immune-related conditions in one patient.

The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.

Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.

Balancing treatment effectiveness with side effects is crucial for relapsed follicular non-Hodgkin's lymphoma, especially in older patients.

Tofacitinib is effective and safe for treating severe hair loss in Korean patients.

Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.

CI-1033 causes skin lesions in rats, similar to humans, due to EGF receptor inhibition.

Upadacitinib effectively treated severe hair loss in a child.

Bendamustine, often combined with other drugs, is effective and less toxic for certain blood cancers, but less effective for young, fit patients with CLL.

Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.

Erlotinib can cause hair loss and scalp issues, which improve after stopping the drug.

Tofacitinib significantly improved skin and hair conditions without side effects.

Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.

Axitinib treatment turned a man's grey hair back to black.

Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.

Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.

Ruxolitinib cream effectively treats skin conditions like atopic dermatitis and vitiligo with minimal side effects.

Bendamustine combined with rituximab is an effective and well-tolerated treatment for certain types of lymphoma.

Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.

Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.

Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.

Tofacitinib is effective and safe for elderly patients with ulcerative colitis.

Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.